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Background. Brain structure appears to alter after antipsychotic administration, but it is unknown whether these
alterations are associated with improvement of psychopathology in patients with schizophrenia. In this study, the
authors explore this relationship.
Method. Altogether, 66 ﬁrst-episode, drug-naive patients with schizophrenia and 23 well-matched healthy controls
underwent brain magnetic resonance imaging scans at baseline. All 23 healthy controls and 42 of the patients were
rescanned after 6 weeks follow-up. The patients received regular antipsychotic treatment during the 6-week period
and their psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and
6 weeks. The diﬀerence in PANSS scores between baseline and 6 weeks was expressed as a ratio of the scores at
baseline – ‘PANSS reduction ratio ’. A modiﬁed tensor-based morphometry procedure was applied to analyse
longitudinal images. Correlations between regional volume changes, PANSS reduction ratio and antipsychotic drug
dosages were explored.
Results. Compared with healthy controls, there was a signiﬁcant increase in grey-matter volume of the right
putamen in patients after 6 weeks treatment. This volume change was positively correlated with a positive PANSS
reduction score but not related to drug dosages.
Conclusions. Putaminal volume increased after 6 weeks antipsychotic treatment in ﬁrst-episode schizophrenia. The
increased volume was closely correlated with improved psychopathology, suggesting the putamen might be a
biomarker to predict the treatment response in schizophrenia.
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Introduction
Numerous studies have reported brain structural
anomalies in patients with schizophrenia, including
expansion of lateral ventricles and abnormalities in
prefrontal and temporal lobes (Shenton et al. 2001 ;
Honea et al. 2005 ; Steen et al. 2006). Some anomalous
features, such as lower temporal lobe volumes, are
even found in ﬁrst-episode, drug-naive patients with
schizophrenia (Jayakumar et al. 2005; Chua et al.
2007 ; Lui et al. 2009). Thus, regional brain volume
abnormalities appear to be an integral component
of the neuropathology of schizophrenia. The impact
of antipsychotics on regional brain volume has also
received attention. Antipsychotics have been reported
to inﬂuence the brain structure, especially regional
grey-matter volumes, such as basal ganglia, cingulate
gyrus and thalamus (Navari & Dazzan, 2009 ;
Smieskova et al. 2009 ; Tomelleri et al. 2009) in patients
with schizophrenia. Some changes such as an increase
in striatal volume might occur even after a very short
period of antipsychotic treatment (Chua et al. 2009 ;
Deng et al. 2009). A short-term follow-up period is
particularly important in studying the brain structures
aﬀected by antipsychotics because, to a certain extent,
this excludes the eﬀects of the progression of the dis-
ease itself. However, short-term follow-up studies are
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challenging and few in number and the relationship
between the brain volume changes and earliest
symptomatic improvement of psychosis has not been
directly examined.
There is a debate on the time course for anti-
psychotic treatment response in schizophrenia. The
early onset theory indicated that the antipsychotic ef-
fect started simultaneously while the drug reached its
therapeutic levels (i.e. in the ﬁrst few days) (Agid et al.
2003 ; Leucht et al. 2005). The delayed onset theory
suggested that a delay exists between the start of
antipsychotic treatment and the improvement of psy-
chiatric symptoms. Emsley and his colleagues found
that, among 522 ﬁrst-episode patients with schizo-
phrenia, treatment response was not achieved until
4 weeks in 22.5%, 8 weeks in 11.2% (Emsley et al.
2006). The current guidelines for the treatment of
schizophrenia still recommend clinicians to allow
4–8 weeks for a patient to respond to an antipsychotic
drug based on the delayed onset theory (Lehman et al.
2004 ; Falkai et al. 2005). Moreover, the eﬀects of the
treatment are still evaluated by assessing the severity
of symptoms mainly with clinical scales such as
Positive and Negative Syndrome Scale (PANSS) or
Brief Psychiatric Rating Scale and there are no con-
ﬁrmed biomarkers to predict the treatment response
objectively.
The purpose of the present study was to quantify
brain structural change in ﬁrst-episode, drug-naive
patients with schizophrenia after 6 weeks antipsy-
chotics treatment and to explore the relationship be-
tween brain volume change and psychopathology
improvement in order to identify potentially biologi-
cal indicators of treatment eﬃcacy.
Subjects and method
Subjects
In total, 66 out-patients and in-patients from the
Mental Health Center in West China Hospital were
enrolled in the present study from July 2005 to March
2008. All patients were experiencing their ﬁrst-episode
of psychosis and were treatment-naive when recruited
to the study. They were assessed by a trained psy-
chiatrist using the Structured Clinical Interview for
the DSM-IV (Diagnostic and Statistical Manual of
Mental Disorders, fourth edition) and were found to
fulﬁl diagnostic criteria for schizophrenia or schizo-
phreniform psychosis as described in DSM-IV. All
patients diagnosed with schizophreniform psychosis
were followed up for at least 6 months and found to
meet the DSM-IV diagnosis criteria of schizophrenia.
Altogether, 23 healthy controls were recruited from
the local area by poster advertisement. All controls
were screened for the lifetime absence of psychiatric
illnesses by using the SCID non-patient version (First
et al. 1996). In addition, control subjects were inter-
viewed to ascertain that there was no psychiatric
illness in their ﬁrst-degree relatives. Subjects with
evidence of organic brain disorders, alcohol or drug
abuse, pregnancy or any severe physical illness, such
as brain tumour or epilepsy, were excluded from the
study. Six weeks was selected as an initial time point
to evaluate the eﬃciency of the antipsychotics treat-
ment according to previous studies (Harris et al. 2006;
Lahti et al. 2009). Before the patients took any anti-
psychotic medication, they all underwent an assess-
ment of psychopathology and social function by an
experienced psychiatrist using PANSS (Kay et al.
1987) and Global Assessment Function (GAF) scale
(Morosini et al. 2000), respectively. All patients and
controls also underwent magnetic resonance imaging
(MRI) brain scans at baseline. At 6 weeks follow-up,
MRI scan was scheduled for 42 patients and all con-
trols. Two patients were excluded from later analysis
due to unsatisfactory image data in the follow-up MRI
scan. All patients with schizophrenia were assessed
with the PANSS and GAF scale to record the changes
in clinical symptoms and global function after 6 weeks
treatment.
In this study, patients with schizophrenia re-
ceived antipsychotic medication according to the case-
clinician’s preference. There were 21, seven, six, two,
three and one patients who took risperidone, olanza-
pine, quetiapine, aripiprazole, sulpiride and haloper-
idol, respectively (Table 1).
All participants were Han Chinese and right-
handed. The handedness of participants was assessed
with the Annett’s Hand Preference Questionnaire
(Annett Handedness Scale) (Annett, 1970). This study
was carried out in accordance with the Declaration
of Helsinki and was approved by the Institutional
Review Board of West China Hospital, Sichuan
University. After a complete description of the study
to the subjects, written informed consent was ob-
tained.
MRI data acquisition
The participants were scanned on a Signa 3.0-T scan-
ner (General Electric, Medical Systems, USA) in the
Department of Radiology at West China Hospital.
A water phantom was scanned to get data quality
assurance indexes every time, which was used to
evaluate the stability of the MRI machine. High resol-
ution T1 images were acquired by 3D spoiled gradient
echo sequence (SPGR) as follows : repetition time
8.5 ms, echo time 3.93 ms, ﬂip angle 12x, slice thickness
1 mm, single shot, ﬁeld of view 24 cmr24 cm, matrix
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256r256 and voxel size 0.47r0.47r1 mm3. This
sequence lasted 6 min and 30 s and 156 contiguous
coronal slices were collected.
Image processing and analysis
The quality of the brain images was examined and two
patients’ images were excluded due to the unsatisfac-
tory images in the 6-week follow-up scan. The non-
parametric, non-uniformity intensity normalization
technique (N3) in MINC software package (http://wiki.
bic.mni.mcgill.ca/index.php/MINC) was used to rec-
tify the non-uniformity of a high-magnetic ﬁeld
signal in the remaining images. The baseline images
were then processed using voxel-based morphometry
in Statistical Parametric Mapping-8 (SPM8; Wellcome
Trust Center for Neuroimaging, Institute of Neur-
ology, UK). Customized templates were created from
the 63 baseline scans ﬁrst, then the grey, white and
cerebrospinal ﬂuid compartments of the baseline
images were obtained by segmenting the original base-
line scans using the customized templates, the indi-
vidual grey-matter images were then normalized to
the customized template and issue volume was pre-
served by modulating voxel value in the grey-matter
images. After that, the longitudinal images were pro-
cessed using tensor-based morphometry (TBM) in
SPM8. Each subject’s image at follow-up was ﬁrst
registered to the baseline image via a rigid body
transformation and then mapped to the baseline im-
age via a high-dimensional deformation. The defor-
mation was then applied to the grey-matter map of the
follow-up image and modulated with the Jacobian
determinant of this transformation. This yielded a
follow-up image in the space of the baseline image, but
with intensities reﬂecting the follow-up image. This
image was transformed to standard space using the
normalization parameters of the baseline images and
modulated to form a product follow-up image. These
grey-matter images were smoothed with a 6-mm, full-
width, half maximum kernel.
A ‘diﬀerence map’ for each individual was cal-
culated from the follow-up smoothed grey-matter im-
age minus the baseline smoothed grey-matter image
and reﬂected the grey-matter volume change between
the two time points (Deng et al. 2009).
Statistical analysis
SPM8 software was used to design the matrix for
comparing the diﬀerence map of the two groups, with
grey-matter volume plus white-matter volume from
the baseline scan, sex, age and education years as
covariates. A signiﬁcance criterion was deﬁned using
p<0.05, with family-wise error rate correction for
multiple comparisons. In the patient group, a volume
of interest (VOI) was used to extract the eigenvariate
values of the region identiﬁed as ‘changed’ during the
6-week period. This VOI was used for further partial
correlation analysis with the changes in PANSS scores,
the drug dosages and changes in GAF score, control-
ling the sex, age and education years in SPSS 15.0
statistical software. The diﬀerence in PANSS scores
and GAF scores between baseline and 6 weeks was
expressed as a ratio of the scores at baseline – ‘PANSS
reduction ratio ’ and ‘GAF increase ratio ’.
Results
Demographic and clinical characteristics
The demographic characteristics of the subjects are
shown in Table 2. Altogether, 14 males and nine
females were recruited as healthy controls, with mean
age=22.48 (S.D.=5.84, range 16–39) years and mean
duration of education=12.80 (S.D.=3.42, range 6.5–19)
years. The 40 patients who entered the analysis in the
present study, including 23 females and 17 males, had
mean age=24.05 (S.D.=7.75, range 16–49) years and
mean duration of education=12.50 (S.D.=2.94, range
4–15) years ; the mean duration of disease of the
patients was 9.33 (S.D.=12.72, range 0.1–60) months
and the mean age of onset was 23.30 (S.D.=7.67, range
16–40) years when they were recruited. A x2 test or
Table 1. Number of patients and dosage for each type antipsychotic
Risperidone Olanzapine Quetiapine Aripiprazole Sulpiride Haloperidol
Number of patients 21 7 6 2 3 1
Dosage/day (mg) 4.42 17.36 616.66 25.46 833.33 16
(¡1.18) (¡8.51) (¡222.86) (¡13.43) (¡152.75) –
CPZ (mg) equivalenta 220.86 347.28 822.21 339.40 416.67 800
(¡58.76) (¡170.11) (¡297.15) (¡179.04) (¡76.38) –
CPZ, chlorpromazine.
a Dosage/day : mean (¡S.D.).
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independent-sample t test was carried out to examine
statistical diﬀerences in sex, age and education years
as appropriate. The dosage of antipsychotic medi-
cation taken by each patient was recorded and con-
verted to chlorpromazine equivalent dosages (Table 1)
(Atkins et al. 1997 ; Woods, 2003). After 6 weeks anti-
psychotic treatment, the PANSS reduction ratio and
GAF increase ratio was calculated (Table 3).
Regional grey-matter changes during 6 weeks
antipsychotic treatment and correlation with drug
dosages and clinical symptom reduction
Compared with healthy controls, the increased grey-
matter volume was identiﬁed in the right putamen
in the patients group following 6 weeks treatment (x=
28, y=3, z=4 ; p=0.003; voxels=31 ; volume=
6.848 mm3) (Fig. 1). The volume change in the right
putamen was found to be positively correlated with
the reduction ratio of positive symptoms, r=0.350,
p=0.034 (Fig. 2). There was no signiﬁcant correlation
with the reduction ratio of negative symptoms, drug
dosages or the improvement of global function meas-
ured by the GAF.
Discussion
In this study, we found that an increased volume in
putamen was associated with positive symptom re-
duction in schizophrenia after 6 weeks antipsychotic
treatment. There are a number of advantages in this
study that help to ensure relatively reliable results.
First, medication-naive patients with ﬁrst-episode
schizophrenia were recruited. By analysing these
valuable data collected, the inﬂuence of confounding
factors, such as the neuron response to previous ex-
posure to antipsychotic and chronic disease course, is
largely controlled. Second, we used TBM to analyse
longitudinal images, which allowed us to perform a
relatively unbiased, whole brain analysis. In this
analysis, each subject’s follow-up image is mapped
Table 3. PANSS and GAF reductive ratio after 6 weeks antipsychotic treatment
Score 0 weeks Score 6 weeks PANSS reduction ratio
Mean S.D. Mean S.D. Mean S.D.
PANSS scores
Total 103.55 15.00 68.50 17.04 0.34 0.14
Positive 26.98 5.99 14.13 4.29 0.46 0.18
Negative 18.63 6.78 15.96 6.28 0.12 0.20
General psychopathology 49.35 8.06 34.05 9.20 0.31 0.15
GAF scores 27.72 7.91 54.15 14.33 26.43 15.51
PANSS, Positive and Negative Syndrome Scale ; GAF, Global Assessment of Functioning.
Table 2. Demographic and clinical characteristics for antipsychotic-naive ﬁrst-episode patients with schizophrenia and healthy
comparison subjects
Patients with schizophrenia
(n=40)
Healthy controls
(n=23)
t (2-tailed) df pMean S.D. Mean S.D.
Age (years) 24.05 7.75 22.49 5.83 x0.84 61 0.40
Duration of education (years) 12.50 2.94 12.80 3.42 0.37 61 0.71
Age of onset (years) 23.30 7.67
Duration of disease (months) 9.33 12.72
n % n % x2 df p
Gender 1.97 1 0.16
Male 17 42.50 14 60.87
Female 23 57.50 9 39.13
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directly to his or her baseline image via rigid body
registration and high-dimensional image warping,
which is sensitive to subtle brain volume growth or
loss. It is particularly suitable for detecting within-
subject volumetric changes over time (Ashburner &
Friston, 2004 ; Leow et al. 2006). Finally, we used SPGR
sequence to obtain images and N3 correction before
TBM processing, and this is considered to be the most
stable sequence with least deviation for mapping brain
changes when using TBM (Leow et al. 2006).
Using TBM, we found an increased volume of
putamen following antipsychotic treatment, in line
with previous studies (Dazzan et al. 2005 ; Taylor et al.
2005). The putamen is located in the rostral part of
the striatum and, together with the caudate nucleus,
forms the dorsal striatum, a subcortical area rich in
dopamine. Dopamine is one of main neurotrans-
mitters in the striatum active in complex cognitive and
behavioural symptoms (Volkow et al. 1998 ; Backman
et al. 2000 ; Reeves et al. 2005 ; Schultz, 2007). Although
the pathophysiological mechanisms underlying
schizophrenia are somewhat obscure, the dopamine
hypothesis remains one of the most inﬂuential (Toda
& Abi-Dargham, 2007; Heinz & Schlagenhauf, 2010).
It is suggested that an excess of dopamine in the sub-
cortical region is associated with positive symptoms,
such as hallucinations, delusions, while the negative
and cognitive symptoms of schizophrenia are thought
to arise from a deﬁcit of dopamine in the cortex
(Jentsch & Roth, 1999; Seeman & Kapur, 2000 ; Abi-
Dargham, 2004; Howes & Kapur, 2009). Consistent
with this, we have previously observed a functional
deﬁcit in the putamen in a resting-state functional MRI
study of treatment-naive, ﬁrst-episode patients with
schizophrenia (Huang et al. 2009). Also, signiﬁcantly
increased activation of the regional cerebral blood
ﬂow in putamen has been found after haloperidol
treatment (Lahti et al. 2009). Others have reported that
patients who were previously medicated had lower
metabolic rates and higher volumes than in never-
medicated patients in the putamen (Gur et al. 1998 ;
Shihabuddin et al. 1998 ; Premkumar et al. 2006). A
later study found that putaminal volumes were de-
creased during the interval if patients discontinued
atypical antipsychotics, while increased in patients
who continued their antipsychotics including olanza-
pine, risperidone, or quetiapine (Boonstra et al. 2011).
Collectively, these results implicate a functional and
structural reaction in the putamen in response to
dopaminergic treatment. However, it should note that
the putaminal volume deﬁcits might not exist in
patients, especially in patients who experienced their
ﬁrst-episode attack or were drug-naive. A few pre-
vious studies showed there is no signiﬁcant volume
diﬀerence in putamen between ﬁrst-episode schizo-
phrenia patients and controls (Gur et al. 1998 ; Lang
et al. 2001 ; Gunduz et al. 2002 ; Lui et al. 2009).
In the present study, we found that only the right
but not the left putaminal volume increased after
6 weeks antipsychotic treatment. This might be related
to striatal asymmetry existing in both patients and
normal healthy controls. Previous studies have sug-
gested that the basal ganglia, like other brain struc-
tures, exhibited hemispheric lateralization. The right
striatal volume was larger than the left striatal volume
in humans (Ifthikharuddin et al. 2000 ; Watkins et al.
2001 ; Yamashita et al. 2011). Left–right asymmetry of
striatal dopamine D2 receptors was also detected by
Larisch and his colleagues, who showed that D2
binding ratio was higher in the right compared to the
left striatum in healthy volunteers (Larisch et al. 1998).
In addition, previous studies using a voxel-based
morphometry method to study the cerebral asym-
metry did not ﬁnd any diﬀerences in grey-matter vol-
ume asymmetry (Takao et al. 2010) or basal ganglia
asymmetry (Kawasaki et al. 2008) between patients
with schizophrenia and healthy controls.
The exact mechanism of enlarged putaminal vol-
ume after antipsychotic treatment is unknown. It
has been suggested that dopamine plays a role not
only as a neurotransmitter but also as a regulator
of endogenous neurogenesis in the adult mammalian
brain (Borta & Hoglinger, 2007). Dopaminegic stimu-
lation in vitro inhibits neural stem cell (NSC) pro-
liferation and haloperidol, as well as risperidone,
dopamine receptor antagonists, may increase adult
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Fig. 1. Diﬀerence map between patients and controls.
Relative to healthy control subjects, patients with
schizophrenia had signiﬁcantly increased grey-matter
volume in the right putamen following 6 weeks antipsychotic
treatment (x=28, y=3, z=4 ; p=0.003 ; voxels=31 ;
volume=6.848 mm3).
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mammalian brain proliferation by antagonizing
dopamine at D-2 receptors on NSCs contributing to
new neurons and glia in the adult rat brain (Kippin
et al. 2005; Keilhoﬀ et al. 2010). The antipsychotic
olanzapine has also been found to signiﬁcantly in-
crease both the total number and density of newly
generated neurons in the prefrontal cortex and dorsal
striatum in rats (Wang et al. 2004). Beckmann & Lauer
(1997) reported that increased striatal volume is ac-
companied by an increased number of striatal neurons
in patients with schizophrenia. Konradi & Heckers
(2001) also concluded that antipsychotic drugs might
induce neuroplasticity. They suggested that the classic
antipsychotic haloperidol has a signiﬁcant eﬀect on
synapse formation and rearrangement, which may be
important for its antipsychotic properties (Konradi &
Heckers, 2001). These studies prompt the speculation
that the increased volume of putamen after 6 weeks
antipsychotic treatment observed here might reﬂect
neurogenesis and neuroplasticity.
In line with previous studies, which showed that
the increased volume in striatum is associated with
a reduction in positive symptoms (Taylor et al. 2005)
and that increased caudate volume is related to the
symptom improvement after olanzapine treatment
(Okugawa et al. 2007), we found that increased
putaminal volume was only positively related to the
ratio of reduction in a positive symptom score in the
current study. This is not consistent with some pre-
vious studies, which showed larger increases in cau-
date volume or putaminal volume associated with a
higher dose of antipsychotic medication (Chakos et al.
1994 ; Gur et al. 1998 ; Beng-Choon et al. 2011) as we did
not observe a relationship between the putaminal vol-
ume changes and the total antipsychotic dosages. This
ﬁnding suggests that, to some extent, the increased
volume in putamen might be a candidate biomarker
to evaluate the eﬃciency of antipsychotic response
in terms of improvement of positive symptoms of
patients. In other words, the results might reﬂect
an individual response to antipsychotic rather than
a more general ﬁxed dose–response. In previous
studies, conventional and atypical antipsychotic
have been considered to act diﬀerently on brain
morphology. Volumetric changes in basal ganglia
were thought to be much more likely with the use of
conventional rather than atypical antipsychotics
(Navari & Dazzan, 2009). Conventional antipsychotics
seemed to aﬀect the basal ganglia (enlargement of the
putamen) and cortical areas more extensively, while
atypical antipsychotics were particularly associated
with enlargement of the thalami (Dazzan et al. 2005). In
the present study, when we removed four subjects
who received conventional antipsychotics, the result
was largely unchanged. This common eﬀect of typical
and atypical medication on basal ganglia volume is
similar to that reported by Massana et al. (2005) after
3-months resperidione treatment and a signiﬁcantly
increased volume in the putamen was detected after
12 weeks of exposure to risperidone by Glenthoj et al.
(2007). These studies agree that both conventional and
atypical antipsychotic have eﬀects on the basal ganglia
in the early stage of treatment of schizophrenia. The
trend towards a signiﬁcant positive correlation be-
tween the increased volume of putamen and the im-
provement of positive symptoms still existed after
excluding four patients who received conventional
antipsychotic (p=0.057, r=0.334), although the
smaller sample size reduced the power to detect the
signiﬁcant correlation.
There are some limitations in this study. First, we
included 66 patients at baseline ; however, only 42
patients rescanned in 6 weeks and 40 patientsk images
qualiﬁed for analysis. The ratio of follow-up is thus
63.64%, which may result in selective bias due to the
willingness of the patients and/or other reasons
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Fig. 2. The volume change in the right putamen was found to be positively correlated with the reduction ratio of positive
symptoms (r=0.350, p=0.034). PANSS, Positive and Negative Syndrome Scale.
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(e.g. lack of response to the treatment, living in remote
areas of the country, etc.). But there is no signiﬁcant
diﬀerence in duration of illness or clinical severity
in 42 re-scanned patients and 24 unable to re-scan
patients groups in baseline (duration of illness : p=
0.9238 ; GAF: p=0.2929 ; PANSS total score : p=0.5835;
PANSS positive symptoms: p=0.1364 ; PANSS nega-
tive symptoms: p=0.1345; PANSS general symptoms:
p=0.3636). Unfortunately, we did not have the treat-
ment history for the subgroup who had not re-scanned
due to various reasons (e.g. lost contact after patients
were discharged from the hospital or unwilling to be
rescanned after treatment, etc.). Second, this is a
naturalistic study regarding the choice of treatment,
so we did not control the type of antipsychotics that
the patients received. Only four patients took conven-
tional antipsychotics, so it was not possible to com-
pare the eﬀects of diﬀerent antipsychotics on brain
structure.
In present-day clinical practice, we are able to ob-
serve if a patient is responding after 6 weeks treatment
by using clinical assessment (e.g. the reduction rate
of positive and negative symptom score). However,
those assessments used in present clinical practice are
rather subjective and unstable and it is diﬃcult to
quantify the degree of treatment response without
identifying objective biomarkers. Thus, it is becoming
a ‘hot ’ area that biomarkers would be better and
promising indicators for assessment of treatment re-
sponse. In this study, we did an explorative analysis
and identiﬁed the increased volume change of pu-
tamen after 6 weeks antipsychotic treatment by using
the MRI scan. In addition, the increased volume was
related to the improvement of positive symptoms in
patients with schizophrenia, which provided sup-
portive evidence for future use in clinical practice.
However, more independent studies are required
to conﬁrm this ﬁnding. Furthermore, it is worthwhile
to seek biomarkers, which may predict treatment re-
sponse at an even earlier stage, e.g. 2 weeks after
treatment, and to identify biomarkers, which may
eventually lead to personalized medication in the
treatment of schizophrenia.
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